Glossary
Prednisone
Prednisone works, which is why it's still used everywhere. The costs that got measured, though, turn out not to be the ones most people brace themselves for. One of them is your strength rather than your bones.
What the research found.
The 2017 American College of Rheumatology guideline covers every adult on a long steroid course, at every age. It strongly advises four things: get your calcium and vitamin D right, do weight-bearing and strength-building exercise, stop smoking, and cut back on alcohol. All four sit outside a prescription.
One study measured bone density in 198 patients with polymyalgia rheumatica, giant cell arteritis, and other kinds of vasculitis, where their steroid dose didn't track with their lowest bone score. Neither the current dose nor the total did. Three other things did: being lighter, having broken a bone in the spine before, and taking a heartburn drug.
One study followed 36 newly diagnosed polymyalgia rheumatica patients, seeing them three months after starting steroids and again 18 months later. At both visits they scored worse on a disability form than 32 matched controls. The differences came out at 0.33 and 0.41, with P values below 0.001.
In that group, more patients than controls were heading toward frailty at both visits. At the first visit it was 71.2 percent against 34.4 percent, which is an odds ratio of 4.7. At follow-up it was 60.7 percent against 34.4 percent.
In polymyalgia rheumatica, two dose measures failed to predict an early calm spell. The prednisone dose at the first visit came out at a P value of 0.32, and the total steroid taken by three months came out at 0.12. One thing did predict it, and that was the change in vitamin D.
What it is and why it's still everywhere
Prednisone is a steroid, and more particularly a made copy of a hormone your adrenal glands produce. It damps inflammation everywhere in the body and it does it fast, which is the reason it stays in use across inflammatory and autoimmune disease whatever else is known about its costs. When something has to be brought under control now, very little else works this quickly.
That mix of real benefit and real cost is what makes this drug hard to write about. A page that only listed the harms would be describing a treatment nobody should take, which isn't the position of anybody who prescribes it. A page that skipped the harms would leave out the reason all the lifestyle advice in these illnesses exists in the first place.
This site holds no source on how the drug works inside a cell, so this page says what it's for rather than how it works. It also gives no dose, no step-down plan, and no expected length of treatment, because those belong to whoever prescribes for you. A figure read off a website is the kind of thing people act on.
Bone density, which doesn't track your dose
Bone loss is the best known long-term risk of this drug, and the link with your dose is far less direct than almost everybody assumes. One study measured 198 patients with polymyalgia rheumatica, giant cell arteritis, and other kinds of vasculitis, where the steroid dose didn't track with the lowest bone score, on either the current dose or the total over time. In both models the numbers sat tight around zero.
Three other things did track with lower bone density, and those were being lighter, having broken a bone in the spine before, and taking a heartburn drug. None of those three is a steroid dose, and two of them are things a person might never think to raise at a rheumatology visit. A heartburn drug in particular tends to get discussed with whoever prescribed it and nowhere else.
Read that study's design and the reason becomes plain. It measured people at one moment, in a bone clinic, and most were already on bone protection, so it can't show what a trial would. When nearly everybody gets protective treatment, a real dose effect can vanish from the numbers, and our record for it says so. Read carefully, it argues for bone protection and against predicting your own risk from your milligrams.
The cost that appeared more clearly
The measurements that separated patients from controls most consistently weren't about bone at all. They were about strength. One study followed 36 newly diagnosed polymyalgia rheumatica patients, seeing them three months after starting steroids and again 18 months later, against 32 controls matched for age and sex. At both visits the patients scored worse on a disability form, at differences of 0.33 and 0.41, with P values below 0.001.
Frailty followed the same path. At the first visit, 71.2 percent of patients were heading toward frailty against 34.4 percent of controls, which is an odds ratio of 4.7, and at follow-up it was still more common, at 60.7 percent against 34.4 percent. Women also slowed down more when walking than female controls and were slower getting out of a chair at follow-up, though both of those came from splitting a small group by sex, so read them as early hints rather than settled results.
One negative finding from that study belongs alongside the rest. Body composition changed no differently in the patients than in the controls over the 18 months. Weight change is the effect people brace for, and it wasn't the one this study caught.
More isn't obviously better
A fair question is whether a higher dose buys a faster result, and one study in our sources speaks to it. In polymyalgia rheumatica, two dose measures failed to predict an early calm spell, where the prednisone dose at the first visit came out at a P value of 0.32 and the total steroid taken by three months came out at 0.12. One thing did predict it in that model, and it was the three-month change in vitamin D.
That study was small, it looked backward, and it only watched what happened, so it can't say what dose is right for anybody. It also can't rule out something simpler, which is that the doses given already matched each patient's severity, and that would flatten any dose link by design. Cause running the other way, and better care overall, are both unaddressed in it.
Here is what it does argue against, which is the assumption that more steroid means faster control. That assumption drives requests for higher doses and reluctance to come down, and the one study we hold that tested the link didn't find one. So it's a question worth putting to a prescriber rather than settling from a website.
What to ask for at the start
Bone protection is the one thing here with a guideline behind it, and the wording is unusually clear. The 2017 American College of Rheumatology guideline covers every adult starting or staying on a long steroid course, at every age. It strongly advises four things: get your calcium and vitamin D right, do weight-bearing and strength-building exercise, stop smoking, and cut back on alcohol. That's one recommendation covering five separate things, all of them outside a prescription.
Two details about it change how you use it. It applies from the day long treatment begins rather than after a problem appears, so ask at the first visit. It also covers all adults on a long steroid course rather than any one illness, so it applies to you whatever you're being treated for.
This page gives no amounts. Our record for that guideline says the full text came back with an error, so the wording got checked against a secondary summary instead and the calcium and vitamin D amounts couldn't be confirmed. Publishing figures nobody here has checked would be worse than saying so and pointing the question at your prescriber.
What this page doesn't cover
The short-term effects are the ones most people want addressed, and this site holds no source on any of them. Sleep trouble, mood change, appetite, blood sugar, and infection risk are all missing from these pages, because no reference in our set speaks to any of them. That's the biggest hole in this entry. It sits in the review notes rather than getting filled in from general knowledge.
Every long-term figure here comes from polymyalgia rheumatica or mixed vasculitis patients, because that's where our steroid sources sit. So somebody taking prednisone for lupus, myositis, or another kind of vasculitis will find no numbers here about their own illness at all. The bone protection guideline is the one item that reaches everybody, because it was written for everybody.
If you've been quoted a figure for any of the missing subjects, asking where it came from is fair. Prednisone attracts more confident unsourced advice than almost anything else in this field, and it comes from both directions, with some people playing down the risks and others warning against a drug somebody needs. Neither position gets better with an invented number.
Common misconceptions.
Myth. A low dose means my bones are safe.
Reality. Dose turned out to be a poor guide to it. One study measured 198 patients with these diagnoses, where their steroid dose didn't track with their lowest bone score, on either the current dose or the total. Three other things did, which were being lighter, having broken a bone in the spine before, and taking a heartburn drug. Those patients were measured at one moment and most were already on bone protection, so it can't replace a trial, and what it does argue is that you shouldn't read your dose as your risk.
Myth. Steroids make you gain weight, and that's the main problem.
Reality. Weight change is real, and it isn't what the measurements flagged as the bigger issue. In the bone study, being lighter was one of the three things that went with worse bone. In the polymyalgia rheumatica group, two things lasted, and those were disability and heading toward frailty, while body composition changed no differently from the controls over 18 months.
Myth. Once I'm on treatment my function will come back.
Reality. It didn't for everybody in the one study that followed it. Patients scored worse than matched controls on a disability form at three months and again 18 months later, at differences of 0.33 and 0.41. Women slowed down more when walking than female controls, and they were slower getting out of a chair at follow-up. Those last two are subgroup findings, so read them as early hints, and what they argue for is treating your strength as a target of its own.
Myth. A higher steroid dose gets you into remission faster.
Reality. In the one study we hold that tested this, it didn't. In polymyalgia rheumatica, two dose measures failed to predict an early calm spell, where the dose at the first visit came out at a P value of 0.32 and the total steroid taken by three months came out at 0.12. That study looked backward and only watched, so it can't say what dose is right, and what it does argue against is assuming more is better.
Related terms.
- Polymyalgia rheumatica and diet, where the bone protection guidance is set out in full.
- Polymyalgia rheumatica and exercise, for the function and frailty findings in full.
- Remission, and why dose didn't predict reaching it in the one study that looked.
- Vitamin D, the test the bone protection recommendation rests on.
Questions patients ask.
What does prednisone do?
It's a steroid, which is to say a made copy of a hormone your adrenal glands produce, and it damps inflammation everywhere in the body, fast. That speed is why it stays in use across these illnesses, whatever its costs. This site holds no source on how it works inside a cell, so this page says what the drug is for rather than explaining the mechanism.
What dose should I be on?
This page gives no doses, and that's on purpose rather than an oversight. The right dose here depends on which illness you have, how bad that illness is, and who you happen to be, and a figure read off a website is the kind of thing people act on. So your prescriber sets it, and asking about the plan for coming down is a fair question to bring to a visit.
Will it damage my bones?
Bone loss is the best known long-term risk, and the link with your dose is less direct than you would expect. One study measured 198 patients on these drugs, where their dose didn't track with their lowest bone score, on either the current dose or the total. Three other things did: being lighter, having broken a bone in the spine before, and taking a heartburn drug. Most of those patients were already on bone protection, so it argues for protection rather than for prediction.
What should I ask for at the start of treatment?
Bone protection is the one thing here with a guideline behind it. The 2017 American College of Rheumatology guideline covers every adult starting or staying on a long steroid course, at every age. It strongly advises four things: get your calcium and vitamin D right, do weight-bearing and strength-building exercise, stop smoking, and cut back on alcohol. So ask at the start rather than months in, which is the practical form of it.
How much calcium and vitamin D?
This page gives no amounts, and the reason is specific. Our record for that guideline says the full text came back with an error, so the wording got checked against a secondary summary instead, and the calcium and vitamin D amounts couldn't be confirmed. Publishing figures nobody here has checked would be worse than saying so, so ask your prescriber for the amounts they use.
Why am I weaker on treatment when my disease is controlled?
One study followed that very question. Newly diagnosed polymyalgia rheumatica patients scored worse than matched controls on a disability form three months after starting steroids and again 18 months later. Women also slowed down more when walking, and were slower getting out of a chair at follow-up, though those last two came from splitting a small group by sex. So read them as early hints rather than as settled findings.
Does a proton-pump inhibitor count here?
It was one of three things that went with lower bone density in that study of 198 patients, alongside being lighter and having broken a bone in the spine before. That's a link found at one moment in time rather than a proven cause. Still, mention it when bone protection comes up, because it's a detail that often never reaches the rheumatology conversation at all.
References.
- Buckley L; Guyatt G; Fink H et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. 2017;69:1521-1537. 10.1002/art.40137GRADE-based clinical practice guideline
- Palmowski A; Wiebe E; Muche B et al. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022;11:536. 10.3390/cells11030536Cross-sectional baseline analysis of a prospective cohort
- Leung J; De Ross B; Gianoudis J et al. Changes to physical function and body composition during the first 2 years of polymyalgia rheumatica. Rheumatology. 2025;64:5834-5843. 10.1093/rheumatology/keaf375Prospective longitudinal case-control cohort
- Hysa E; Balito S; Davoli G et al. Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation. Nutrients. 2025;17:2839. 10.3390/nu17172839Retrospective observational case-control study with a longitudinal subgroup
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.